Summary:
- This article discusses the results of a phase 1 clinical trial for a new drug called SKY-0515, developed by a company called Skyhawks Therapeutics.
- The drug is being tested as a potential treatment for Huntington's disease, a rare genetic disorder that affects the brain and causes progressive movement, cognitive, and psychiatric problems.
- The phase 1 trial was designed to assess the safety and tolerability of the drug in healthy volunteers, and the results indicate that SKY-0515 was well-tolerated and did not cause any significant side effects.